Last reviewed · How we verify

NCT06810427: CervImage

A Novel, Low-Cost, Handheld 3D Imaging System for Improved Screening for Cervical Neoplasia in Resource-Limited Settings

Active, enrolled NA Last updated 18 March 2026
What this trial tests

NA trial testing CervImage device in Cervical Intraepithelial Neoplasia in 18 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
16 January 2025
Primary endpoint
16 May 2025
31 July 2026

Quick facts

Lead sponsorCarilion Clinic
PhaseNA
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposedevice feasibility
Enrollment18
Start date16 January 2025
Primary completion16 May 2025
Estimated completion31 July 2026
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Carilion Clinic

Who can join

Adults 21 to 70, female only, with Cervical Intraepithelial Neoplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the design and engineering of a new minimally invasive medical imaging device (CervImage™). Investigators are trying to find out if CervImage™ is reliable and easy to use to obtain clinical 3D photographs and to record 3D measurements in human cervixes. Investigators then plan to use these images to determine if CervImage™ design and engineering improvements need to be made.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cervical Intraepithelial Neoplasia

Currently open trials in the same condition.

Other Carilion Clinic trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06810427.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing